Kanamycin Sulfate


|Kanamycin Sulfate

Drugs search, click the first letter of a drug name:

| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Kanamycin Sulfate

Pronouncation: (kan-uh-MY-sin SULL-fate)
Class: Aminoglycoside

Trade Names:
- Capsules 500 mg
- Injection 500 mg
- Injection 1 g
- Pediatric Injection 75 mg

Mechanism of Action


Inhibits production of bacterial protein, causing cell death.



Rapidly absorbed after IM injection. T max is approximately 1 hr. C max is 22 mcg/mL (from the 7.5 mg/kg dose). Poorly absorbed from the normal GI tract (orally).


Diffuses rapidly into most body fluids including synovial and peritoneal fluids and bile. Significant levels of drug appear in cord blood and amniotic fluid.


Little if any metabolic transformation occurs.


Plasma t ½ is 2 hr.

Excreted almost entirely by glomerular filtration and is not reabsorbed by the renal tubules. Renal excretion is extremely rapid. The unabsorbed portion is eliminated unchanged in the feces.


48 to 72 hr

Special Populations

Renal Function Impairment

Patients with renal function impairment or diminished glomerular pressure excrete kanamycin more slowly. May build up excessively high blood levels that lead to increased risk of ototoxic reactions.

Severely burned patients

In severely burned patients, t ½ may significantly decrease. As result serum concentrations may be lower.

Indications and Usage


Short-term treatment of serious infections caused by susceptible strains of microorganisms, especially gram-negative bacteria.


Short-term adjunctive therapy for suppression of intestinal bacteria; treatment of hepatic coma.


Hypersensitivity to aminoglycosides; intestinal obstruction (oral). Generally not indicated for long-term therapy (more than 14 days) because of ototoxicity and nephrotoxicity.

Dosage and Administration

Adults and Children

IM/IV 15 mg/kg/day in 2 to 4 divided doses. Do not exceed 1.5 g/day.

Suppression of Intestinal Bacteria

PO 1 g qh for 4 hr, then 1 g q 6 hr for 36 to 72 hr.

Adults and children

IM/IV 15 to 30 mg/kg/day (max, 1 g/day).

Hepatic Coma

PO 8 to 12 g/day in divided doses.

General Advice

  • For IV administration, dilute each 500 mg with 100 to 200 mL or more of 0.9% sodium chloride or D5W. Give slowly over 30 to 60 min.
  • Give IM injection deeply into upper outer quadrant of gluteal muscle.


Store at room temperature. Darkening of vials during shelf life does not indicate loss of potency.

Drug Interactions

Beta-lactam antibiotics (eg, cephalosporins, penicillins)

Do not mix in IV solutions.

Digoxin, methotrexate, vitamin A, vitamin K

Oral kanamycin may decrease absorption of these drugs.

Drugs with nephrotoxic potential (eg, amphotericin, cephalosporins, enflurane, methoxyflurane, vancomycin)

Increased risk of nephrotoxicity.

Loop diuretics

Increased auditory toxicity.

Neuromuscular blocking agents

Enhanced effects of these agents.

Polypeptide antibiotics

Increased risk of respiratory paralysis and renal dysfunction.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Neuromuscular blockade.


Hearing loss; deafness; loss of balance.


Malabsorption syndrome (eg, increased fecal fat, decreased serum carotene, fall in xylose absorption); nausea; vomiting; diarrhea.


Oliguria; proteinuria; elevated serum creatinine and BUN; granular casts; red and white cells in urine; decreased Ccr.




Pain and irritation at injection site; acute muscular paralysis; hypomagnesemia.




Manifests as both auditory and vestibular ototoxicity, and primarily occurs in patients with preexisting renal damage with prolonged therapy. Partial or total irreversible deafness may continue to develop after drug is stopped. Other features of neurotoxicity include paresthesia, twitching, and seizures.


Usually reversible.

Teratogenic in pregnancy.

Closely monitor renal and eighth nerve function in patients with suspected renal dysfunction. Monitor peak and trough concentrations. Dosage adjustments are required in renal impairment.


Category D .


Excreted in breast milk.


Use cautiously in premature infants and newborns because of renal immaturity.

Neuromuscular blockade

Use with caution in patients with neuromuscular disorders, those receiving anesthesia or muscle relaxants, hypomagnesemia, hypocalcemia, hypokalemia, or in newborns whose mothers received magnesium sulfate.

Oral absorption

Increased absorption (and potential for toxicity) when intestinal mucosa is ulcerated or denuded.



Nephrotoxicity, auditory toxicity, vestibular toxicity, neuromuscular blockade, respiratory paralysis.

Patient Information

  • Advise patient that drug may cause nausea, vomiting, or diarrhea.
  • Instruct patient to drink plenty of fluids while taking medication.
  • Emphasize importance of follow-up visits and serial audiograms, because ototoxicity may be asymptomatic.
  • Instruct patient to report the following symptoms to health care provider: ringing in ears, hearing impairment, rash, difficulty urinating, or dizziness.

Where can I get more information about Kanamycin Sulfate ? We recommend to use www.Drugs.com

Typical mistypes for Kanamycin Sulfate
janamycin sulfate, manamycin sulfate, lanamycin sulfate, oanamycin sulfate, ianamycin sulfate, kznamycin sulfate, ksnamycin sulfate, kwnamycin sulfate, kqnamycin sulfate, kabamycin sulfate, kamamycin sulfate, kajamycin sulfate, kahamycin sulfate, kanzmycin sulfate, kansmycin sulfate, kanwmycin sulfate, kanqmycin sulfate, kananycin sulfate, kanakycin sulfate, kanajycin sulfate, kanamtcin sulfate, kanamgcin sulfate, kanamhcin sulfate, kanamucin sulfate, kanam7cin sulfate, kanam6cin sulfate, kanamyxin sulfate, kanamyvin sulfate, kanamyfin sulfate, kanamydin sulfate, kanamycun sulfate, kanamycjn sulfate, kanamyckn sulfate, kanamycon sulfate, kanamyc9n sulfate, kanamyc8n sulfate, kanamycib sulfate, kanamycim sulfate, kanamycij sulfate, kanamycih sulfate, kanamycin aulfate, kanamycin zulfate, kanamycin xulfate, kanamycin dulfate, kanamycin eulfate, kanamycin wulfate, kanamycin sylfate, kanamycin shlfate, kanamycin sjlfate, kanamycin silfate, kanamycin s8lfate, kanamycin s7lfate, kanamycin sukfate, kanamycin supfate, kanamycin suofate, kanamycin suldate, kanamycin sulcate, kanamycin sulvate, kanamycin sulgate, kanamycin sultate, kanamycin sulrate, kanamycin sulfzte, kanamycin sulfste, kanamycin sulfwte, kanamycin sulfqte, kanamycin sulfare, kanamycin sulfafe, kanamycin sulfage, kanamycin sulfaye, kanamycin sulfa6e, kanamycin sulfa5e, kanamycin sulfatw, kanamycin sulfats, kanamycin sulfatd, kanamycin sulfatr, kanamycin sulfat4, kanamycin sulfat3, anamycin sulfate, knamycin sulfate, kaamycin sulfate, kanmycin sulfate, kanaycin sulfate, kanamcin sulfate, kanamyin sulfate, kanamycn sulfate, kanamyci sulfate, kanamycinsulfate, kanamycin ulfate, kanamycin slfate, kanamycin sufate, kanamycin sulate, kanamycin sulfte, kanamycin sulfae, kanamycin sulfat, aknamycin sulfate, knaamycin sulfate, kaanmycin sulfate, kanmaycin sulfate, kanaymcin sulfate, kanamcyin sulfate, kanamyicn sulfate, kanamycni sulfate, kanamyci nsulfate, kanamycins ulfate, kanamycin uslfate, kanamycin slufate, kanamycin suflate, kanamycin sulafte, kanamycin sulftae, kanamycin sulfaet, kkanamycin sulfate, kaanamycin sulfate, kannamycin sulfate, kanaamycin sulfate, kanammycin sulfate, kanamyycin sulfate, kanamyccin sulfate, kanamyciin sulfate, kanamycinn sulfate, kanamycin sulfate, kanamycin ssulfate, kanamycin suulfate, kanamycin sullfate, kanamycin sulffate, kanamycin sulfaate, kanamycin sulfatte, kanamycin sulfatee, etc.

© Copyright by drug-information.ru 2001-2019. All rights reserved